AbCellera Biologics Inc. ABCL Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $128.51M-17.8% | $156.33M+17.3% | $133.32M-65.5% | $386.54M-18.8% | ||
| $39.41M+23.2% | $31.98M— | —— | —— | ||
| $6.34M— | —— | —— | —— | ||
| $728.23M-3.1% | $751.37M-13.8% | $871.99M-15.0% | $1.03B+10.3% | ||
| $47.81M0.0% | $47.81M0.0% | $47.81M0.0% | $47.81M0.0% | ||
| $38.38M-8.9% | $42.11M-65.0% | $120.43M-8.4% | $131.5M-11.4% | ||
| $628.72M+3.2% | $609.18M-1.1% | $616.11M+19.5% | $515.42M+32.6% | ||
| $1.36B-0.3% | $1.36B-8.6% | $1.49B-3.4% | $1.54B+16.9% | ||
| $25.23M-26.6% | $34.35M+20.1% | $28.6M+92.9% | $14.83M— | ||
| $13.53M0.0% | $13.52M-28.7% | $18.96M-12.3% | $21.61M+187% | ||
| $64.31M-16.1% | $76.61M-35.6% | $119.01M+0.6% | $118.32M-2.0% | ||
| $325.74M+43.0% | $227.86M+5.1% | $216.76M+14.5% | $189.31M+10.0% | ||
| $390.05M+28.1% | $304.47M-9.3% | $335.78M+9.1% | $307.63M+5.1% | ||
| $802.34M+3.2% | $777.17M+3.2% | $753.2M+2.6% | $734.37M+1.7% | ||
| -$29.48M-125% | $116.93M-58.2% | $279.79M-34.4% | $426.19M+59.2% | ||
| $966.9M-8.4% | $1.06B-8.4% | $1.15B-6.6% | $1.23B+20.2% | ||
| $1.36B-0.3% | $1.36B-8.6% | $1.49B-3.4% | $1.54B+16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can AbCellera Biologics Inc. cover its short-term obligations?
- Its current ratio is 14.05 — current assets exceed current liabilities.
- Where does AbCellera Biologics Inc.'s balance sheet data come from?
- Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.